Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 10 January 2018 | By Zachary Brennan
The European Medicines Agency (EMA) on Wednesday announced the adoption of a guideline, first drafted in 2011, on the clinical evaluation of medicinal products in the treatment of the autoimmune disease rheumatoid arthritis (RA).
"Currently, several biomarkers which may predict disease progression and response are under development. In the future, this may lead to a more individually targeted treatment approach," the guideline said. "Despite significant advances in the treatment of RA in the last decade, there are still a considerable number of patients who do not tolerate or who are resistant to available pharmacological treatment options. New treatment options are therefore in demand."
The guideline, which is set to take effect 1 July 2018, features sections on the criteria and standards for patient selection, possible indications or treatment goals, how to assess efficacy, the strategy and design of clinical trials, clinical safety evaluations and studies in special populations including the elderly and children.
"This document is a revision of the Points to Consider adopted in November 2003," EMA said. "Pharmacological therapy has advanced for RA in the last decade. Therapeutic strategies employing more intensive intervention in early disease, often using combinations of non-biologic and biologic DMARDs [disease-modifying anti-rheumatic drugs], have shown a faster onset of action and more profound clinical responses than traditional approaches."
EMA noted that the optimum treatment goal is remission, or at least low disease activity in patients that do not respond to earlier treatments.
In terms of what has changed since 2003, the guideline said new classification criteria for RA have been developed and validated by the American College of Rheumatology’s European League against Rheumatism that allows for earlier DMARD use.
"This has led to new endpoints reflecting treatment targets of remission or low-disease activity at earlier time points, in place of the previous primary endpoint of meeting ACR20 improvement criteria at 6 months. Furthermore, a distinction is currently made in this Guideline between trials in DMARD-naïve RA patients or in patients who have had an inadequate response (IR) to prior therapy with DMARDs. Recommendations are also introduced on how to measure the prevention of structural bone damage," the guideline adds.
Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis
Tags: rheumatoid arthritis, EMA guideline
Regulatory Focus newsletters
All the biggest regulatory news and happenings.